These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37853676)

  • 1. Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study.
    Panarelli JF; Bowden EC; Tepedino ME; Odani-Kawabata N; Pei Z; McLaurin EB; Ropo A
    J Glaucoma; 2023 Dec; 32(12):999-1005. PubMed ID: 37853676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
    Aihara M; Ropo A; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams N
    Jpn J Ophthalmol; 2020 Jul; 64(4):398-406. PubMed ID: 32572719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension: The Phase 3 AYAME Study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N; Shams NK
    Am J Ophthalmol; 2020 Dec; 220():53-63. PubMed ID: 32533949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.
    Wang TH; Aung T; Lu DW; George R; Senthil S; Lu F; Odani-Kawabata N; Park KH
    Clin Ophthalmol; 2024; 18():2093-2106. PubMed ID: 39051019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
    Bacharach J; Brubaker JW; Evans DG; Lu F; Odani-Kawabata N; Yamabe T; Wirta DL
    Am J Ophthalmol; 2024 Jul; 263():23-34. PubMed ID: 38395329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study.
    Aihara M; Lu F; Kawata H; Iwata A; Odani-Kawabata N
    Jpn J Ophthalmol; 2021 Nov; 65(6):810-819. PubMed ID: 34495425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan.
    Miki A; Miyamoto E; Ishida N; Shii D; Hori K;
    Adv Ther; 2022 May; 39(5):2085-2095. PubMed ID: 35287233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan.
    Nakazawa T; Takahashi K; Kuwayama Y; Nomura A; Shimada F
    Adv Ther; 2022 Mar; 39(3):1359-1374. PubMed ID: 35072890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension.
    Aihara M; Lu F; Kawata H; Iwata A; Liu K; Odani-Kawabata N; Shams NK
    J Glaucoma; 2019 May; 28(5):375-385. PubMed ID: 30839416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6).
    Olander KW; Sato MA; Abrams MA; Jerkins GW; Lu F; Dinh P; Odani-Kawabata N; Chabi A; Shams NK
    J Glaucoma; 2021 Jun; 30(6):473-480. PubMed ID: 33813559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
    Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
    Kandarakis S; Papadopoulos AP; Roussopoulos G; Georgopoulos E; Chung Y; Doumazos L; Baek A; Paizi NI; Shin H; Papadopoulos PA
    Expert Opin Drug Saf; 2024 Jun; 23(6):743-754. PubMed ID: 37674345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.
    Schachar RA; Raber S; Courtney R; Zhang M
    Curr Eye Res; 2011 Sep; 36(9):809-17. PubMed ID: 21851167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
    Kuo HT; Yeh CY; Hsu AY; Ho JH; Lin CJ; Tsai YY
    J Ocul Pharmacol Ther; 2023 Dec; 39(10):705-715. PubMed ID: 37579061
    [No Abstract]   [Full Text] [Related]  

  • 19. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
    Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.